Effects of the angiotensin-converting enzyme inhibitor enalapril on blood haematopoietic progenitors and acetyl-N-Ser-Asp-Lys-Pro concentrations.
Acetyl-N-Ser-Asp-Lys-Pro (AcSDKP) is a physiological inhibitor of the proliferation of haematopoietic stem cells. In 12 healthy volunteers treated with the angiotensin-converting enzyme (ACE) inhibitor enalapril (20 mg day-1 for 15 days), we studied plasma and urinary AcSDKP levels, the in vitro degradation of AcSDKP by plasma ACE and the numbers of circulating haematopoietic progenitors (granulocyte-monocytic colony forming unit: CFU-GM; burst forming unit-erythroid: BFU-E; and mixed colony forming unit: CFU-mixed). During treatment, plasma and urinary AcSDKP concentrations increased 2- to 5-fold, degradation of AcSDKP was reduced, and CFU-mixed significantly increased by 100% while BFU-E and CFU-GM significantly decreased by 16% and 26%, respectively. These results indicate that ACE inhibitors may be of value during chemotherapy or radiotherapy, warranting further study.
Comte
L
L
Laboratoire d'Hématologie Expérimentale, Faculté de Médicine, Limoges, France.
Lorgeot
V
V
Volkov
L
L
Allegraud
A
A
Aldigier
J C
JC
Praloran
V
V
D000328:Adult; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology*; D004656:Enalapril / Q000494:pharmacology*; D015672:Erythroid Precursor Cells / Q000187:drug effects; D006131:Growth Inhibitors / Q000378:metabolism* / Q000494:pharmacology; D006412:Hematopoietic Stem Cells / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009842:Oligopeptides / Q000097:blood / Q000378:metabolism* / Q000652:urine
D000806:Angiotensin-Converting Enzyme Inhibitors; D006131:Growth Inhibitors; D009842:Oligopeptides; D004656:Enalapril; C058504:goralatide